
Migraine Science
MRI Study Reveals Brain Differences in Patients with Migraine, Offering Hope for Better Diagnostics and Treatment
A recent study published in the journal Neurology has found interesting observations on the brain structure of people with migraine. The study compared MRI scans of 296 migraine patients to 155 healthy controls, analyzing cortical surface area, thickness, and volume.
The researchers found that migraine patients, especially those with chronic migraine, had reduced cortical surface area in the left anterior insula, a region involved in pain processing. They also discovered increased surface area in the right caudal anterior cingulate cortex (ACC) in chronic migraine, which correlated with monthly headache frequency. Furthermore, migraine without aura was associated with greater right caudal ACC surface area compared to controls.
No significant differences in cortical thickness or volume were found between migraine and control groups.
The study's findings have important implications for people with migraine. The distinct brain signatures observed in different migraine subtypes suggest that personalized diagnostics and therapies may be possible in the future.
The association between medication overuse/adaptation headache and brain structure changes also highlights the need for effective preventive treatments.
Finally, this is also further evidence that migraine is not “just in your head” as some therapy people we recently talked about like to claim. It is not fear-based, but real, anatomical, and functional changes occurring in the nervous system, including the brain.
Where to next?
Pick a topic and dive into more free, research-backed guides in the Migraine Resource Hub.
Vestibular Rehabilitation for Vestibular Migraine: What 7 Studies Show
Seven studies and 272 adults with vestibular migraine show a pooled 23.97 point drop in dizziness handicap after vestibular rehabilitation, above the usual threshold for clinical meaningfulness. Balance confidence did...
Read MoreBotox for Chronic Migraine: What 479 Real-World Patients Show
A 479-patient real-world study of onabotulinumtoxinA for chronic migraine found a mean reduction of 5.9 monthly headache days, with 27.3% reaching the 50% response threshold and 41.6% shedding medication overuse....
Read MoreThe New Migraine Prevention Guideline: What the AAN and AHS Recommend
The American Academy of Neurology and the American Headache Society have published a joint practice guideline on migraine prevention in adults: 17 recommendations and 52 statements. It names no single...
Read More








